Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neurology

Symptoms, Milestones, and What to Expect

At a Glance

CADASIL symptoms typically progress from migraines with aura in young adulthood to mini-strokes and executive dysfunction in mid-to-late life. Unlike Alzheimer's disease, early cognitive changes impact planning and processing speed rather than memory.

CADASIL is a progressive condition, but its path is rarely a straight line. Because the disease affects the tiny blood vessels throughout the brain, the symptoms you experience depend on which areas of the brain are currently being affected [1]. While there is a common “timeline” of symptoms, it is important to remember that progression is highly variable—even among members of the same family with the identical genetic mutation [2][3].

A General Map of the CADASIL Journey

Most patients follow a general progression through adulthood, though the age of onset for each milestone can vary by decades [4].

  • Young Adulthood (20s–30s): The most frequent early symptom is migraine with aura [4][5]. This isn’t a standard headache; it often involves visual disturbances (like flashing lights) or tingling sensations before the pain begins. For some, these migraines are the only sign for many years [6].
  • Mid-Adulthood (40s–50s): This is often when “ischemic events” begin. These can be TIAs (Transient Ischemic Attacks or “mini-strokes”) or full ischemic strokes [7][8]. These events occur when a small vessel becomes blocked. Over time, these small events can add up, even if they don’t cause immediate, obvious disability [9].
  • Later Adulthood (60s and beyond): As the “burden” of small strokes and white matter changes increases, cognitive and mood changes may become more prominent [9][4].

Understanding “Executive Function” vs. Memory

One of the most important things to understand about CADASIL is that it affects the brain differently than Alzheimer’s disease. In Alzheimer’s, the first sign is usually losing “episodic memory” (forgetting what you did yesterday). In CADASIL, the decline often hits executive function first [10][11].

Executive dysfunction affects your “command center” and might look like:

  • Difficulty planning a complex task or following a recipe [12].
  • A “slowing down” of thoughts and processing speed [10].
  • Trouble organizing your day or switching between two different tasks [11].
  • Reduced attention span or feeling easily overwhelmed by “brain fog.”

Because your memory for facts and faces might stay sharp for a long time, these early executive struggles are often missed by standard memory tests [13].

Mood and Psychiatric Changes

CADASIL doesn’t just affect how you think; it can affect how you feel. Up to 30% of patients experience mood disturbances [5][4].

  • Apathy: This is one of the most common but misunderstood symptoms. It is a loss of “drive” or motivation [14]. It is not the same as being lazy or sad; it is a physical result of the brain’s “action-initiation” networks being disrupted [15]. Critically, apathy is frequently misdiagnosed as depression, which can lead to ineffective psychiatric treatment [16].
  • Depression and Anxiety: These are very common and can be a reaction to the diagnosis or a direct result of the vascular changes in the brain [17].
  • Personality Changes: Some patients experience late-onset changes in personality, such as becoming more impulsive or irritable [16][18].

The Risk of Brain Bleeds (Hemorrhage)

While most CADASIL events are caused by blocked vessels (ischemia), some patients are at risk for intracerebral hemorrhage (bleeding in the brain) [19]. This risk is not the same for everyone:

  • Genetic Variants: Certain mutations, specifically the R544C and R75P variants (more common in East Asian populations), carry a higher risk of bleeding [20][21].
  • Hypertension: High blood pressure is the single biggest “additive” risk factor [20][22]. If you have both a high-risk mutation and high blood pressure, the risk of a bleed increases significantly [20].
  • Microbleeds: Doctors can see tiny “microbleeds” on an MRI. A high number of these is often a warning sign that the brain’s vessels are becoming more fragile [19][23].

Common questions in this guide

What are the first signs of CADASIL?
For most people, the earliest symptom is a migraine with an aura, typically starting in their 20s or 30s. These migraines often involve visual disturbances, like flashing lights, or tingling sensations before the head pain begins.
How does CADASIL affect memory and thinking?
CADASIL often affects your executive function rather than your short-term memory. You might notice a slowing of your processing speed, brain fog, or difficulty planning complex tasks and switching between activities.
Is apathy the same thing as depression in CADASIL?
Apathy is a physical result of disrupted networks in the brain that causes a severe loss of motivation or drive. While it can look similar to depression from the outside, it is a distinct symptom that is frequently misdiagnosed.
Do all CADASIL patients have a high risk of brain bleeds?
Not everyone has the same risk of bleeding in the brain. The risk is significantly higher for individuals with certain genetic variants, like R544C and R75P, especially if they also have high blood pressure.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific mutation, how often should I be screened for microbleeds or cognitive changes?
  2. 2.How can we differentiate whether my mood changes are primary depression or apathy related to my small vessel disease?
  3. 3.Are there specific types of cognitive therapy or 'brain training' that focus on executive function?
  4. 4.If I have the R544C or R75P variant, should I be on any blood-thinning medications, or is the risk of bleeding too high?
  5. 5.What are the signs of a 'silent' stroke that I should be watching for?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Cadasil syndrome: A case report with a literature review.

    Lahkim M, Laamrani FZ, Andour H, et al.

    Radiology case reports 2021; (16(11)):3540-3543 doi:10.1016/j.radcr.2021.08.023.

    PMID: 34584593
  2. 2

    Novel mutation of the NOTCH3 gene in a Polish family with CADASIL.

    Buczek J, Błażejewska-Hyżorek B, Cudna A, et al.

    Neurologia i neurochirurgia polska 2016; (50(4)):262-4.

    PMID: 27375140
  3. 3

    CADASIL or NOTCH3 mutaion spectrum diseases? Interpretation of NOTCH3 mutations and clinical heterogeneity in CADASIL.

    Wang Y, Liu Y, Mo H, et al.

    Frontiers in neurology 2025; (16()):1662012 doi:10.3389/fneur.2025.1662012.

    PMID: 41018180
  4. 4

    [The hereditary vessel disease CADASIL].

    Sveinsson OA, Arkink EB, Thors B

    Laeknabladid 2024; (110(7)):360-364 doi:10.17992/lbl.2024.0708.801.

    PMID: 38934718
  5. 5

    Ataxia Associated with CADASIL: a Pathology-Confirmed Case Report and Literature Review.

    Park DG, Min JH, Sohn SH, et al.

    Cerebellum (London, England) 2020; (19(6)):907-910 doi:10.1007/s12311-020-01173-z.

    PMID: 32734377
  6. 6

    The Spectrum of NOTCH3 Variants in an Australian CADASIL Cohort.

    Guyler SK, Tsai J, Maksemous N, et al.

    Genes 2025; (16(11)) doi:10.3390/genes16111353.

    PMID: 41300806
  7. 7

    Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) - Still to be Considered in the Presence of Vascular Risk Factors.

    Ganesan DN, Coste T, Venketasubramanian N

    Case reports in neurology 2020; (12(Suppl 1)):196-201 doi:10.1159/000507542.

    PMID: 33505295
  8. 8

    Heterozygous Cysteine-sparing NOTCH3 Variant p.Val237Met in a Japanese Patient with Suspected Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy.

    Kano Y, Mizuta I, Ueda A, et al.

    Internal medicine (Tokyo, Japan) 2021; (60(15)):2479-2482 doi:10.2169/internalmedicine.6096-20.

    PMID: 33678736
  9. 9

    Imaging Characteristics for Predicting Cognitive Impairment in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy.

    Taniguchi A, Shindo A, Tabei KI, et al.

    Frontiers in aging neuroscience 2022; (14()):876437 doi:10.3389/fnagi.2022.876437.

    PMID: 35754959
  10. 10

    Specific Abnormalities in White Matter Pathways as Interface to Small Vessels Disease and Cognition in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Individuals.

    Jacobs HIL, Schoemaker D, Torrico-Teave H, et al.

    Brain connectivity 2022; (12(1)):52-60 doi:10.1089/brain.2020.0980.

    PMID: 33980027
  11. 11

    Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Syndrome: A Case Report and Review of Literature.

    Gutierrez Gomez C, Lopez Gonzalez MDA, Vazquez Tobias AN, Rivera Chávez JG

    Cureus 2024; (16(2)):e53469 doi:10.7759/cureus.53469.

    PMID: 38435179
  12. 12

    Diffuse Tract Damage in CADASIL Is Correlated with Global Cognitive Impairment.

    Ban S, Wang H, Wang M, et al.

    European neurology 2019; (81(5-6)):294-301 doi:10.1159/000501612.

    PMID: 31484188
  13. 13

    The INECO Frontal Screening for the Evaluation of Executive Dysfunction in Cerebral Small Vessel Disease: Evidence from Quantitative MRI in a CADASIL Cohort from Colombia.

    Schoemaker D, Zuluaga Y, Viswanathan A, et al.

    Journal of the International Neuropsychological Society : JINS 2020; (26(10)):1006-1018 doi:10.1017/S1355617720000533.

    PMID: 32487276
  14. 14

    Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic review and meta-analysis.

    Clancy U, Gilmartin D, Jochems ACC, et al.

    The lancet. Psychiatry 2021; (8(3)):225-236 doi:10.1016/S2215-0366(20)30431-4.

    PMID: 33539776
  15. 15

    Apathy is associated with large-scale white matter network disruption in small vessel disease.

    Tay J, Tuladhar AM, Hollocks MJ, et al.

    Neurology 2019; (92(11)):e1157-e1167 doi:10.1212/WNL.0000000000007095.

    PMID: 30737341
  16. 16

    CADASIL presenting as late-onset mania with anosognosia.

    Uppal M, Kanellopoulos D, Kotbi N

    Clinical case reports 2020; (8(1)):47-50 doi:10.1002/ccr3.2594.

    PMID: 31998484
  17. 17

    [Treatment-refractory chronic depression in a CADASIL patient with a symptom-free somatic course: a case report].

    Wurthmann S, Kastrup O, Wurthmann C, et al.

    Fortschritte der Neurologie-Psychiatrie 2025; (93(7-08)):306-310 doi:10.1055/a-2512-7605.

    PMID: 39919799
  18. 18

    CADASIL Syndrome Presenting as Obsessive-Compulsive Disorder: A Case Report.

    Canlı D, Keskin M

    Noro psikiyatri arsivi 2025; (62(1)):90-93 doi:10.29399/npa.28683.

    PMID: 40046195
  19. 19

    Intracerebral Hemorrhage in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy: Prevalence, Clinical and Neuroimaging Features and Risk Factors.

    Liao YC, Hu YC, Chung CP, et al.

    Stroke 2021; (52(3)):985-993 doi:10.1161/STROKEAHA.120.030664.

    PMID: 33535780
  20. 20

    Intracerebral Hemorrhage in Patients With CADASIL: Additive Impact of the NOTCH3 R544C Variant and Hypertension?

    Chen CH, Cheng YW, Zhang R, et al.

    Stroke 2025; (56(8)):2159-2166 doi:10.1161/STROKEAHA.124.050484.

    PMID: 40270244
  21. 21

    Pro-Hemorrhagic Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Associated with NOTCH3 p.R75P Mutation with Low Vascular NOTCH3 Aggregation Property.

    Ishiyama H, Kim H, Saito S, et al.

    Annals of neurology 2024; (95(6)):1040-1054 doi:10.1002/ana.26916.

    PMID: 38520151
  22. 22

    Cerebral Microbleeds, Hypertension, and Intracerebral Hemorrhage in Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy.

    Lee JS, Ko K, Oh JH, et al.

    Frontiers in neurology 2017; (8()):203 doi:10.3389/fneur.2017.00203.

    PMID: 28555127
  23. 23

    Occurrence of Intracranial Hemorrhage and Associated Risk Factors in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy: A Systematic Review and Meta-Analysis.

    Lai QL, Zhang YX, Wang JJ, et al.

    Journal of clinical neurology (Seoul, Korea) 2022; (18(5)):499-506 doi:10.3988/jcn.2022.18.5.499.

    PMID: 36062766

This page explains the progression and typical symptoms of CADASIL for educational purposes only. Always consult your neurologist or healthcare provider to monitor your specific symptoms, brain scans, and disease progression.

Get notified when new evidence is published on Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.